Degussa Corp. to Take Full Control of Proligo

Aug 22, 2001

NEW YORK, Aug. 22 – Gilead Sciences is selling its 49 percent interest in oligonucleotides manufacturer Proligo to Degussa Corporation, which currently holds the remaining Proligo shares, the company announced on Wednesday.

The deal, expected to close on Aug. 31, is for $14 million in cash, according to Foster City, Calif.-based Gilead.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Nucleic Acids Research

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

Round and Round We Go

A BMJ study says that about half of former hematology-oncology regulators now work for industry.

Goodbye and Godspeed

Science should wish PhDs who leave academia well, a Nature editorial says.

New Baby Boy

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.

Main menu